Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Authors
Keywords
-
Journal
Frontiers in Cardiovascular Medicine
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-10-29
DOI
10.3389/fcvm.2021.764038
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dynamin-related protein 1 inhibition reduces hepatic PCSK9 secretion
- (2021) Maximillian A Rogers et al. CARDIOVASCULAR RESEARCH
- Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
- (2021) R. Scott Wright et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
- (2021) Juanjuan Yuan et al. Protein & Cell
- Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents
- (2021) Tian–Yun Fan et al. BIOORGANIC CHEMISTRY
- A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9
- (2021) Markus Zeitlinger et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
- (2021) Kiran Musunuru et al. NATURE
- Functional analysis of PCSK9 3′UTR variants and mRNA–miRNA interactions in patients with familial hypercholesterolemia
- (2021) Bruna Los et al. Epigenomics
- PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
- (2021) Shi-Zhe Zhang et al. Experimental Hematology & Oncology
- Substantial PCSK9 inactivation in β-cells does not modify glucose homeostasis or insulin secretion in mice
- (2021) Marie-Line Peyot et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Atherosclerosis-associated hepatic secretion of VLDL but not PCSK9 is dependent on cargo receptor protein Surf4
- (2021) Bingxiang Wang et al. JOURNAL OF LIPID RESEARCH
- MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice
- (2021) Xiaoding Xu et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
- (2020) Gerald F. Watts et al. Nature Reviews Cardiology
- A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α
- (2020) Xuelei Wang et al. EBioMedicine
- Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a
- (2020) Chuan-Jue Cui et al. Journal of Translational Medicine
- The role of the C-terminal domain of PCSK9 and SEC24 isoforms in PCSK9 secretion
- (2020) Shi-jun Deng et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- New Pharmacological Approaches to Target PCSK9
- (2020) Alberico L. Catapano et al. Current Atherosclerosis Reports
- Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia
- (2020) Dirk J. Blom et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- PCSK9 post-transcriptional regulation: role of a 3’UTR microRNA-binding site variant in linkage disequilibrium with c.1420G
- (2020) Charlotte Decourt et al. ATHEROSCLEROSIS
- Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression
- (2020) Dandan Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
- (2020) Qianyun Guo et al. Frontiers in Genetics
- PCSK9: Associated with cardiac diseases and their risk factors?
- (2020) Yanan Guo et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes
- (2020) Marja-Riitta Taskinen et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors
- (2020) Ioannis Farmakis et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
- (2020) Julius L. Katzmann et al. Frontiers in Physiology
- microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
- (2020) Jianjie Dong et al. JCI Insight
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study
- (2019) Tim Hollstein et al. VASCULAR PHARMACOLOGY
- The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (Cajanus cajan (L.) Millsp.) Leaves on Regulating LDLR and PCSK9 Expression in HepG2 Cells
- (2019) Heng-Yuan Chang et al. MOLECULES
- Hypolipidaemia among patients with PMM2-CDG is associated with low circulating PCSK9 levels: a case report followed by observational and experimental studies
- (2019) Michael Chong et al. JOURNAL OF MEDICAL GENETICS
- Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor)
- (2019) Ali Ben Djoudi Ouadda et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Blood flow patterns regulate PCSK9 secretion via MyD88-mediated pro-inflammatory cytokines
- (2019) Shijie Liu et al. CARDIOVASCULAR RESEARCH
- Surf4 regulates expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) but is not required for PCSK9 secretion in cultured human hepatocytes
- (2019) Yishi Shen et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
- (2019) Marja-Riitta Taskinen et al. Journal of Clinical Lipidology
- Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells
- (2018) Wan-Yun Gao et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained
- (2018) Paul Lebeau et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma PCSK9 correlates with apoB-48-containing TG-rich lipoprotein production in men with insulin resistance
- (2018) Jean-Philippe Drouin-Chartier et al. JOURNAL OF LIPID RESEARCH
- Structure and evolution of the Fam20 kinases
- (2018) Hui Zhang et al. Nature Communications
- PCSK9 induces a pro-inflammatory response in macrophages
- (2018) Chiara Ricci et al. Scientific Reports
- Inhibiting PCSK9 — biology beyond LDL control
- (2018) Robert M. Stoekenbroek et al. Nature Reviews Endocrinology
- Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype
- (2017) John S. Chorba et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription
- (2017) Cecilia Patitucci et al. JOURNAL OF CLINICAL INVESTIGATION
- PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
- (2017) Hua Sun et al. JOURNAL OF LIPID RESEARCH
- Methylomic profiling and replication implicates deregulation of PCSK9 in alcohol use disorder
- (2017) F W Lohoff et al. MOLECULAR PSYCHIATRY
- Regulation of PCSK9 by nutraceuticals
- (2017) Amir Abbas Momtazi et al. PHARMACOLOGICAL RESEARCH
- Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
- (2017) Si-Shun Gan et al. OncoTargets and Therapy
- PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
- (2017) Xiaohui Xu et al. Experimental and Therapeutic Medicine
- Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
- (2017) Camilla Gustafsen et al. Nature Communications
- Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
- (2017) Parisa Naeli et al. Frontiers in Genetics
- Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease
- (2017) Marc P. Bonaca et al. CIRCULATION
- Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective
- (2016) Gissette Reyes-Soffer et al. CIRCULATION
- Pairing beyond the Seed Supports MicroRNA Targeting Specificity
- (2016) James P. Broughton et al. MOLECULAR CELL
- Tanshinone IIA Modulates Low Density Lipoprotein Uptake via Down-Regulation of PCSK9 Gene Expression in HepG2 Cells
- (2016) Hung-Chen Chen et al. PLoS One
- Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
- (2015) Zufeng Ding et al. ANTIOXIDANTS & REDOX SIGNALING
- MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis
- (2015) M. Lucrecia Alvarez et al. ATHEROSCLEROSIS
- A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
- (2015) Joseph L. Goldstein et al. CELL
- Statin Intolerance
- (2015) David H. Fitchett et al. CIRCULATION
- Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice
- (2015) Z. Lin et al. CIRCULATION
- Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other
- (2015) Chutikarn Butkinaree et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Local effects of human PCSK9 on the atherosclerotic lesion
- (2015) Ilaria Giunzioni et al. JOURNAL OF PATHOLOGY
- The Hypercholesterolemia-Risk Gene SORT1 Facilitates PCSK9 Secretion
- (2014) Camilla Gustafsen et al. Cell Metabolism
- Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor–Dependent and –Independent Mechanisms
- (2014) Shirya Rashid et al. CIRCULATION
- Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells
- (2014) Mi-Hsueh Tai et al. MOLECULAR NUTRITION & FOOD RESEARCH
- FoxO3 Transcription Factor and Sirt6 Deacetylase Regulate Low Density Lipoprotein (LDL)-cholesterol Homeostasis via Control of the Proprotein Convertase Subtilisin/Kexin Type 9 (Pcsk9) Gene Expression
- (2013) Rongya Tao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
- (2013) Rachel M. DeVay et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding
- (2013) Hong-mei Gu et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
- (2013) Bertrand Cariou et al. Nutrition & Metabolism
- The novel function of HINFP as a co-activator in sterol-regulated transcription ofPCSK9in HepG2 cells
- (2012) Hai Li et al. BIOCHEMICAL JOURNAL
- The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway
- (2012) Yascara Grisel Luna Saavedra et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Loss- and Gain-of-function PCSK9 Variants
- (2012) Suzanne Benjannet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice
- (2012) Ding Ai et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR
- (2012) Yan Wang et al. JOURNAL OF LIPID RESEARCH
- Discovery of a New Role of Human Resistin in Hepatocyte Low-Density Lipoprotein Receptor Suppression Mediated in Part by Proprotein Convertase Subtilisin/Kexin Type 9
- (2012) Michelle Melone et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- SILAC-based quantitative proteomic analysis of gastric cancer secretome
- (2012) Arivusudar Marimuthu et al. Proteomics Clinical Applications
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
- (2011) Nicola Ferri et al. ATHEROSCLEROSIS
- Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification
- (2011) K. Tveten et al. HUMAN MOLECULAR GENETICS
- Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein
- (2011) Fen Du et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
- (2010) Taichi Yamamoto et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein lipase: from gene to obesity
- (2009) Hong Wang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Proprotein Convertase Subtilisin Kexin Type 9 Null Mice Are Protected From Postprandial Triglyceridemia
- (2009) Cédric Le May et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans
- (2008) Thilina Dewpura et al. FEBS Journal
- Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
- (2008) Cédric Langhi et al. FEBS LETTERS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9
- (2008) Sanae Kourimate et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A New PCSK9 Gene Promoter Variant Affects Gene Expression and Causes Autosomal Dominant Hypercholesterolemia
- (2008) Sebastian Blesa et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started